Posted AT 2:22 PM EDT on 20/10/05
Diabetes pill comes under fire
Chicago —
A new diabetes pill that appeared headed for U.S. federal approval can double the risk for deaths, heart attacks and strokes, according to an independent analysis rushed on-line Thursday because of public safety concerns.
The drug muraglitazar, developed by Bristol-Myers Squibb and Merck & Co. to be sold under the name Pargluva, was endorsed by a Food and Drug Administration panel last month.
The full text of this article has 564 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
Child's View 
- Focus on malaria
- Scenes from life in Liberia
Earlier discussion
slideshow
- Medical marijuna
- Alison Myrden's painful battle with MS
Features
- Confronting cancer
- Globe Series concludes with look at people who blaze trails
- Battling cancer
- Breast cancer death rates declining
-
Special report:
A day in the life
4In pictures
- Best position in bed
- How you sleep can make you feel better or worse
